ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+81.75%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$99.4M
AUM Growth
+$99.4M
(-19%)
Cap. Flow
-$15.6M
Cap. Flow
% of AUM
-15.66%
Top 10 Holdings %
Top 10 Hldgs %
60.37%
Holding
49
New
8
Increased
12
Reduced
15
Closed
10
Top Buys
| 1 |
DRUG
Bright Minds Biosciences
DRUG
|
$2.49M |
| 2 |
Trevi Therapeutics
TRVI
|
$1.98M |
| 3 |
Cidara Therapeutics
CDTX
|
$1.46M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$1.29M |
| 5 |
Zymeworks
ZYME
|
$984K |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$7.4M |
| 2 |
Arcellx
ACLX
|
$3.94M |
| 3 |
Kura Oncology
KURA
|
$3.85M |
| 4 |
CMPS
Compass Pathways
CMPS
|
$2.43M |
| 5 |
Taysha Gene Therapies
TSHA
|
$2.14M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $9.49M | 9.55% | 1,111,071 -79,000 | -7% | -$675K |
|
2
Insmed
INSM
$28.8B
| $7.24M | 7.28% | 104,800 -2,700 | -3% | -$186K |
|
3
Tourmaline Bio
TRML
$601M
| $7.14M | 7.18% | 351,842 +19,747 | +6% | +$400K |
|
4
Crinetics Pharmaceuticals
CRNX
$2.92B
| $6.28M | 6.32% | 122,900 -8,800 | -7% | -$450K |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $6.02M | 6.05% | 267,368 -29,000 | -10% | -$653K |
|
|
WHWK
6
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.1M
| $5.83M | 5.87% | 1,849,402 | – | – |
|
7
Praxis Precision Medicines
PRAX
$958M
| $5.19M | 5.23% | 67,500 +10,000 | +17% | +$770K |
|
8
Revolution Medicines
RVMD
$7.1B
| $4.89M | 4.92% | 111,700 +3,700 | +3% | +$162K |
|
9
argenx
ARGX
$43.6B
| $4.25M | 4.28% | 6,910 +1,010 | +17% | +$621K |
|
|
10
Vaxcyte
PCVX
$4B
| $3.68M | 3.71% | 45,000 -90,400 | -67% | -$7.4M |
|
|
11
Trevi Therapeutics
TRVI
$883M
| $3.18M | 3.2% | 771,958 +481,458 | +166% | +$1.98M |
|
12
Ascendis Pharma
ASND
$11.8B
| $3.16M | 3.18% | 22,976 +1,976 | +9% | +$272K |
|
|
MREO
13
Mereo BioPharma
MREO
$272M
| $2.73M | 2.74% | 779,308 -481,392 | -38% | -$1.68M |
|
|
DRUG
14
Bright Minds Biosciences
DRUG
$276M
| $2.49M | 2.5% | +69,124 | New | +$2.49M |
|
15
Terns Pharmaceuticals
TERN
$609M
| $2.48M | 2.49% | 447,500 -39,500 | -8% | -$219K |
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $2.34M | 2.35% | 87,658 +24,658 | +39% | +$658K |
|
|
BBOT
17
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $1.9M | 1.91% | 180,945 | – | – |
|
18
Unicycive Therapeutics
UNCY
$74M
| $1.83M | 1.84% | 2,303,000 +323,801 | +16% | +$257K |
|
19
Rocket Pharmaceuticals
RCKT
$354M
| $1.69M | 1.7% | 134,500 -55,500 | -29% | -$698K |
|
20
Liquidia Corp
LQDA
$2.38B
| $1.62M | 1.63% | 137,709 +64,209 | +87% | +$755K |
|
21
Mersana Therapeutics
MRSN
$36.5M
| $1.6M | 1.61% | 1,120,500 -79,500 | -7% | -$114K |
|
|
22
Taysha Gene Therapies
TSHA
$797M
| $1.53M | 1.54% | 884,244 -1,234,748 | -58% | -$2.14M |
|
|
TECX
23
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $1.52M | 1.53% | 33,008 +19,308 | +141% | +$891K |
|
|
24
Cidara Therapeutics
CDTX
$1.66B
| $1.46M | 1.47% | +54,473 | New | +$1.46M |
|
|
25
NewAmsterdam Pharma
NAMS
$2.71B
| $1.29M | 1.29% | +50,000 | New | +$1.29M |
|